 |
 |

Porphyria Cutanea TardaReport of a Case Effectively Treated With Dimercaprol (BAL)
ALLAN G. REDEKER, M.D.;
REX E. STERLING, Ph.D.;
BERYL ARCHER
AMA Arch Intern Med. 1959;104(5):779-782.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
Porphyria cutanea tarda (PCT) is one of the inborn porphyrinopathies. It is characterized by abnormal porphyrin synthesis and excretion, cutaneous photodynamic activity, fragility of the skin, and, usually, evidence of liver disease. Schmid, Schwartz, and Watson 1 termed porphyria cutanea tarda and acute intermittent porphyria as hepatic porphyrias, a group of disorders very distinct from congenital (erythropoietic) porphyria. Waldenström2 recognized two forms of porphyria cutanea tarda. One form is familial (PCT hereditaria) and becomes clinically manifest shortly after puberty. It may occasionally be complicated by features of acute porphyria, including the excretion of porphobilinogen in the urine. The other form (PCT symptomatica) becomes manifest later in life and is associated with alcoholism or alcoholic cirrhosis and, in rare instances, with tumors of the liver.
The treatment of porphyria cutanea tarda has been generally disappointing. However, some reports of treatment with dimercaprol (BAL) or edathamil (ethylenediaminetetraacetic acid)3-5 have been
. . . [Full Text PDF of this Article]
Author Affiliations
Los Angeles
From the Department of Medicine and the Department of Biochemistry and Nutrition, University of Southern California School of Medicine, and the Los Angeles County General Hospital. Instructor in Medicine (Dr. Redeker), Assistant Professor of Biochemistry and Nutrition (Dr. Sterling).
Footnotes
Submitted for publication March 2, 1959.
This work was supported by a grant from the National Institutes of Health, U. S. Public Health Service (A-1271-C2).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|